{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T11:34:09Z","timestamp":1648812849026},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[1990,1,1]],"date-time":"1990-01-01T00:00:00Z","timestamp":631152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1990]]},"DOI":"10.1007\/bf00685429","type":"journal-article","created":{"date-parts":[[2004,11,28]],"date-time":"2004-11-28T16:59:32Z","timestamp":1101661172000},"page":"S81-S84","source":"Crossref","is-referenced-by-count":6,"title":["Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines"],"prefix":"10.1007","volume":"26","author":[{"given":"Joaquin","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serafin","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis-Alfonso","family":"Sol\ufffd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"861","volume":"58","author":"DL Ahman","year":"1974","unstructured":"Ahman DL, Bisel HF, Hahn RG (1974) Phase II clinical trial of isophosphamide (NSC-109724) in patients with advanced breast cancer. Cancer Chemother Rep 58: 861","journal-title":"Cancer Chemother Rep"},{"key":"CR2","first-page":"59","volume":"16","author":"R Becher","year":"1989","unstructured":"Becher R, H\u00f6feler H, Kloke O, Kurschel E, Schilcher RB, Weinhardt O, Schmidt CG (1989) Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer. Semin Oncol 16: 59","journal-title":"Semin Oncol"},{"key":"CR3","first-page":"224","volume":"23","author":"D Belpomme","year":"1987","unstructured":"Belpomme D, Gisselbrecht C, Marty M, Cour V, Hertier F, Le Rol A, Mignot L, Maral J (1987) Long duration of response induced by vindesine, mitoxantrone and mitomycin C in metastatic breast carcinoma. Proc ASCO 23: 224","journal-title":"Proc ASCO"},{"key":"CR4","first-page":"5","volume":"3","author":"WP Brade","year":"1985","unstructured":"Brade WP, Seeber S, Herdrich K (1985) Experimental and clinical comparative activity of ifosfamide and cyclophosphamide. In: Recent experience with ifosfamide\/mesna in solid tumors. Proc ECCO 3: 5","journal-title":"Proc ECCO"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0277-5379(87)90075-7","volume":"23","author":"VH Bramwell","year":"1987","unstructured":"Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, Van Oosterom A (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23: 311","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR6","first-page":"122","volume":"5","author":"F Brema","year":"1977","unstructured":"Brema F, Porcile GF, Parodi GC (1977) Clinical evaluation of isophosphamide in solid epithelial advanced tumors. Clin Pharmacol Ther 5: 122","journal-title":"Clin Pharmacol Ther"},{"key":"CR7","first-page":"209","volume":"23","author":"J Carmo-Pereira","year":"1987","unstructured":"Carmo-Pereira J, Costa FO, Henriques E, Carvalho V, Catineho-Lopes MG, Grodinho F, Sales-Luis A (1987) First-line chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study. Proc ASCO 23: 209","journal-title":"Proc ASCO"},{"key":"CR8","first-page":"3","volume":"11","author":"FE Durr","year":"1984","unstructured":"Durr FE (1984) Biological and biochemical effects of mitoxantrone. Semin Oncol 11: 3","journal-title":"Semin Oncol"},{"key":"CR9","first-page":"81","volume":"1","author":"N Gad-el-Mawla","year":"1984","unstructured":"Gad-el-Mawla N, Hamza MR, El-Serafi M (1984) Ifosfamide, methotrexate, and fluorouracil effective combination in refractory breast cancer. J Egypt Natl Cancer Inst 1: 81","journal-title":"J Egypt Natl Cancer Inst"},{"key":"CR10","first-page":"14","volume":"4","author":"A Goldin","year":"1982","unstructured":"Goldin A (1982) Ifosfamide in experimental tumor system. Semin Oncol 4: 14","journal-title":"Semin Oncol"},{"key":"CR11","doi-asserted-by":"crossref","unstructured":"Hartlapp JH, Wolter H, Musch E, Illiger HJ (1986) Third line chemotherapy in metastasized breast cancer. Proceedings of the 14th International Cancer Congress, Budapest 51: 735","DOI":"10.1007\/BF02580080"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/1097-0142(19830615)51:12+<2553::AID-CNCR2820511329>3.0.CO;2-7","volume":"51","author":"IC Henderson","year":"1983","unstructured":"Henderson IC (1983) Chemotherapy of breast cancer. A general overview. Cancer 51: 2553","journal-title":"Cancer"},{"key":"CR13","first-page":"67","volume":"20","author":"G Hoffman","year":"1986","unstructured":"Hoffman G, Worst P, Heim ME (1986) Ifosfamide and etoposide as second line therapy in advanced breast cancer. Proceedings of the 12th Annual Meeting of ESMO 20: 67","journal-title":"Proceedings of the 12th Annual Meeting of ESMO"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0277-5379(84)90157-3","volume":"20","author":"A Howell","year":"1984","unstructured":"Howell A, Morrison JM, Bramwell VH (1984) Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer. Eur J Cancer Clin Oncol 20: 873","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR15","first-page":"17","volume-title":"Clinical progress with mitoxantrone","author":"M Kaufmann","year":"1987","unstructured":"Kaufmann M, Manegold C, Schmid H, Kubli F (1987) Phase II study of mitoxantrone and prednimustine in advanced breast cancer. In: Bonadonna G (ed) Clinical progress with mitoxantrone. Royal Society of Medicine Services, London, p 17"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/1097-0142(19810915)48:6<1295::AID-CNCR2820480607>3.0.CO;2-H","volume":"48","author":"PH Konits","year":"1981","unstructured":"Konits PH, Aisner J, Van Echo DA Lichtenfeld K, Wiernik PH (1981) Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 48: 1295","journal-title":"Cancer"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF00174160","volume":"3","author":"K Landys","year":"1985","unstructured":"Landys K, Borgstrom S, Andersson T, Noppa H (1985) Mitoxantrone as a first line treatment of advanced breast cancer. Invest New Drugs 3: 133","journal-title":"Invest New Drugs"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000225625","volume":"39","author":"SS Legha","year":"1982","unstructured":"Legha SS, Blumenschein GR (1982) Systemic therapy of metastatic breast cancer: A review of the current trends. Oncology 39: 140","journal-title":"Oncology"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0305-7372(85)90007-6","volume":"12","author":"L Lenaz","year":"1985","unstructured":"Lenaz L (1985) Mitomycin C in advanced breast cancer. Cancer Treat Rev 12: 235","journal-title":"Cancer Treat Rev"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/1097-0142(19841001)54:7<1252::AID-CNCR2820540703>3.0.CO;2-6","volume":"54","author":"SD Luikart","year":"1984","unstructured":"Luikart SD, Witman GB, Portlock CS (1984) Adriamycin (doxorubicin), vinblastine, and mitomycin-C combination chemotherapy in refractory breast carcinoma. Cancer 54: 1252","journal-title":"Cancer"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000226702","volume":"46","author":"M Navarro","year":"1989","unstructured":"Navarro M, Bellmunt J, Bala\u00f1o C, Colomer R, Jolis L, Del Campo JM (1989) Mitomycin-C,s vinblastine in advanced breast cancer. Oncology 46: 137","journal-title":"Oncology"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1200\/JCO.1986.4.5.672","volume":"4","author":"JA Neidhart","year":"1986","unstructured":"Neidhart JA, Gochnour D, Roach R, Hoth D, Young D (1986) A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672","journal-title":"J Clin Oncol"},{"key":"CR23","first-page":"790","volume":"98","author":"E Petru","year":"1986","unstructured":"Petru E, Schm\u00e4l D (1986) On the relevance of ?second line? cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations. Wien Klin Wochenschrift 98: 790","journal-title":"Wien Klin Wochenschrift"},{"issue":"4","key":"CR24","first-page":"130","volume":"497","author":"J Preiss","year":"1987","unstructured":"Preiss J, Hilfrich J, Corterier H, Rauschecker H, Hohlweg-Majert P, Bodenstein H (1987) Novantrone and Sterecyt in metastatic breast cancer: a multicenter study with first and second line therapy. ECCO [4] 497: 130","journal-title":"ECCO"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00263896","volume":"15","author":"DA Vorobiof","year":"1985","unstructured":"Vorobiof DA, Iturralde M, Falkson G (1985) Assessment of ventricular function by radionuclide angiography in patients receiving 4?-epidoxorubicin and mitoxantrone. Cancer Chemother Pharmacol 15: 253","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/0003-4819-95-6-694","volume":"95","author":"Hy Yap","year":"1981","unstructured":"Yap Hy, Blumenschein GR, Schell FC, Buzdar AV, Valdivieso M, Bodey GP (1981) Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95: 694","journal-title":"Ann Intern Med"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00000421-198210000-00008","volume":"5","author":"HY Yap","year":"1982","unstructured":"Yap HY, Blumenschein GR, Hortobagyi GN, Buzdar AU, Schell FC, Bodey GP (1982) Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol 5: 511","journal-title":"Am J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00685429\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00685429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:10:25Z","timestamp":1554459025000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00685429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990]]},"references-count":27,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1990]]}},"alternative-id":["BF00685429"],"URL":"https:\/\/doi.org\/10.1007\/bf00685429","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990]]}}}